Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil
Olmesartan medoxomil is an angiotensin type II receptor blocker, antihypertensive agent, administered orally. It is highly lipophilic (log P 5.5) and a poorly water-soluble drug with absolute bioavailability of 26%. The poor dissolution rate of water-insoluble drugs is still a major problem confront...
Saved in:
| Published in: | Journal of Drug Delivery Vol. 2013; no. 2013; pp. 283 - 291 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Cairo, Egypt
Hindawi Limiteds
01-01-2013
Hindawi Puplishing Corporation Hindawi Publishing Corporation John Wiley & Sons, Inc |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Olmesartan medoxomil is an angiotensin type II receptor blocker, antihypertensive agent, administered orally. It is highly lipophilic (log P 5.5) and a poorly water-soluble drug with absolute bioavailability of 26%. The poor dissolution rate of water-insoluble drugs is still a major problem confronting the pharmaceutical industry. The objective of the present investigation was to develop liquisolid compacts for olmesartan medoxomil to improve the dissolution rate. Liquisolid compacts were prepared using Acrysol El 135 as a solvent, Avicel PH 102, Fujicalin and Neusilin as carrier materials, and Aerosil as coating material in different ratios. The interaction between drug and excipients was characterized by DSC and FT-IR studies, which showed that there is no interaction between drug and excipients. The powder characteristics were evaluated by different flow parameters to comply with pharmacopoeial limits. The dissolution studies for liquisolid compacts and conventional formulations were carried out, and it was found that liquisolid compacts with 80% w/w of Acrysol EL 135 to the drug showed significant higher drug release rates than conventional tablets. Amongst carriers used Fujicalin and Neusilin were found to be more effective carrier materials for liquid adsorption. |
|---|---|
| AbstractList | Olmesartan medoxomil is an angiotensin type II receptor blocker, antihypertensive agent, administered orally. It is highly lipophilic (log P 5.5) and a poorly water-soluble drug with absolute bioavailability of 26%. The poor dissolution rate of water-insoluble drugs is still a major problem confronting the pharmaceutical industry. The objective of the present investigation was to develop liquisolid compacts for olmesartan medoxomil to improve the dissolution rate. Liquisolid compacts were prepared using Acrysol El 135 as a solvent, Avicel PH 102, Fujicalin and Neusilin as carrier materials, and Aerosil as coating material in different ratios. The interaction between drug and excipients was characterized by DSC and FT-IR studies, which showed that there is no interaction between drug and excipients. The powder characteristics were evaluated by different flow parameters to comply with pharmacopoeial limits. The dissolution studies for liquisolid compacts and conventional formulations were carried out, and it was found that liquisolid compacts with 80% w/w of Acrysol EL 135 to the drug showed significant higher drug release rates than conventional tablets. Amongst carriers used Fujicalin and Neusilin were found to be more effective carrier materials for liquid adsorption. Olmesartan medoxomil is an angiotensin type II receptor blocker, antihypertensive agent, administered orally. It is highly lipophilic (log P 5.5) and a poorly water-soluble drug with absolute bioavailability of 26%. The poor dissolution rate of water-insoluble drugs is still a major problem confronting the pharmaceutical industry. The objective of the present investigation was to develop liquisolid compacts for olmesartan medoxomil to improve the dissolution rate. Liquisolid compacts were prepared using Acrysol El 135 as a solvent, Avicel PH 102, Fujicalin and Neusilin as carrier materials, and Aerosil as coating material in different ratios. The interaction between drug and excipients was characterized by DSC and FT-IR studies, which showed that there is no interaction between drug and excipients. The powder characteristics were evaluated by different flow parameters to comply with pharmacopoeial limits. The dissolution studies for liquisolid compacts and conventional formulations were carried out, and it was found that liquisolid compacts with 80% w/w of Acrysol EL 135 to the drug showed significant higher drug release rates than conventional tablets. Amongst carriers used Fujicalin and Neusilin were found to be more effective carrier materials for liquid adsorption. |
| Audience | Academic |
| Author | Chhaganbhai N. Patel Dashrath M. Patel Shailesh T. Prajapati Suresh K. Dumaniya Hitesh H. Bulchandani |
| AuthorAffiliation | 1 Department of Pharmaceutics, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat 384001, India 2 Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat 384001, India |
| AuthorAffiliation_xml | – name: 1 Department of Pharmaceutics, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat 384001, India – name: 2 Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat 384001, India |
| Author_xml | – sequence: 1 fullname: Prajapati, Shailesh T. – sequence: 2 fullname: Bulchandani, Hitesh H. – sequence: 3 fullname: Patel, Dasharath M. – sequence: 4 fullname: Dumaniya, Suresh K. – sequence: 5 fullname: Patel, Chhaganbhai N. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24232077$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkttrFDEUxgep2It98lkZEESUbU9uk8mLUJbWCyv1QZ9DZibppmSSbTJT639vplOXrggmDycn-Z0P8p1zWOz54HVRvEBwghBjpxgQOa05MC6eFAcYBCwIYLy3PSO6XxyndA150RoEh2fFPqaYYOD8oPhyEWI_OjXY4Evlu_L8VrlxToMpV_ZmtCk425XL0G9UO6TShFheul4nFQfly6-6C3eht-558dQol_TxQzwqflycf19-WqwuP35enq0WihE2LLSiSCHOGoIN8A5YbTjVqMW6bqnhxoCpGGqwUF0DLaZCd6SqO2gqmuFWk6Piw6y7GZted632Q1RObqLtVfwlg7Jy98XbtbwKt5LUqK4FzwJvHwRiuBl1GmRvU6udU16HMUlEmUCMVKLK6OsZvVJOS-tNyIrthMszwquqRuhe8OQfVN6d7m2bG2Zsvt8pePOoYK2VG9bZ5XGyPe2C72ewjSGlqM32mwjkNAByGgA5D0CmXz12Zsv-aXcG3s3A2vpO_bT_UXs5wzoj2qgtzIAKPHmzmt-VjXaw8jqM0efGy29ZhSEMBKC6V0R4CjwPZAWA6V9JTSQWiPwGZkLWVw |
| CitedBy_id | crossref_primary_10_1155_2015_608435 crossref_primary_10_3390_polym13142272 crossref_primary_10_1016_j_jddst_2019_101422 crossref_primary_10_1016_j_ejps_2021_105952 crossref_primary_10_1208_s12249_018_1207_9 crossref_primary_10_1016_j_colsurfb_2017_03_006 crossref_primary_10_2174_1574885515999200424082315 crossref_primary_10_1517_17425247_2015_1059419 crossref_primary_10_1080_03639045_2020_1847136 crossref_primary_10_1179_1433075X15Y_0000000049 crossref_primary_10_1016_j_jddst_2020_102022 crossref_primary_10_2174_0115701638258285230921025512 crossref_primary_10_1021_ie404373n crossref_primary_10_3390_pharmaceutics10030074 crossref_primary_10_1016_j_colsurfb_2018_11_044 crossref_primary_10_1208_s12249_020_01780_3 crossref_primary_10_1208_s12249_023_02635_3 crossref_primary_10_52711_2321_5844_2023_00005 |
| Cites_doi | 10.1016/S0378-5173(01)00867-5 10.1111/j.1524-6175.2002.01051.x 10.1021/js970346g 10.1124/dmd.105.008888 10.2165/00003495-200262090-00005 10.2478/v10298-012-0061-2 10.1111/j.1365-2125.1988.tb03318.x 10.1016/j.ijpharm.2007.03.034 |
| ContentType | Journal Article |
| Contributor | Prajapati, Shailesh T Patel, Chhaganbhai N Bulchandani, Hitesh H Patel, Dasharath M Dumaniya, Suresh K |
| Contributor_xml | – sequence: 1 fullname: Prajapati, Shailesh T – sequence: 2 fullname: Bulchandani, Hitesh H – sequence: 3 fullname: Patel, Dasharath M – sequence: 4 fullname: Dumaniya, Suresh K – sequence: 5 fullname: Patel, Chhaganbhai N |
| Copyright | Copyright © 2013 Shailesh T. Prajapati et al. COPYRIGHT 2013 John Wiley & Sons, Inc. Copyright © 2013 Shailesh T. Prajapati et al. 2013 |
| Copyright_xml | – notice: Copyright © 2013 Shailesh T. Prajapati et al. – notice: COPYRIGHT 2013 John Wiley & Sons, Inc. – notice: Copyright © 2013 Shailesh T. Prajapati et al. 2013 |
| DBID | 188 ADJCN AHFXO RHU RHW RHX NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1155/2013/870579 |
| DatabaseName | Airiti Library الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete Hindawi Publishing Complete Hindawi Publishing Subscription Journals Open Access Journals (Hindawi Publishing) PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2090-3022 |
| Editor | Maincent, Philippe |
| Editor_xml | – sequence: 1 givenname: Philippe surname: Maincent fullname: Maincent, Philippe |
| EndPage | 291 |
| ExternalDocumentID | A376681197 10_1155_2013_870579 24232077 504926 P20151203006_201312_201709060024_201709060024_283_291 |
| Genre | Journal Article |
| GeographicLocations | India |
| GeographicLocations_xml | – name: India |
| GroupedDBID | --- 188 24P 2UF 4.4 53G 5VS AAJEY ABDBF ADBBV ADRAZ AINHJ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CEFSP CNMHZ DIK EBD EBS EJD ESX GROUPED_DOAJ GX1 H13 HYE IAO IEA IHR IHW IL9 INH INR ITC KQ8 M48 M~E O5R OK1 PGMZT RHX RNS RPM TUS UZ5 ADJCN AHFXO O5S RHU RHW NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-a535t-ea41a175b32f07d058f74e1c2e8c4f7ff0f651b29adb0c249ed368d0b64d05ce3 |
| IEDL.DBID | RPM |
| ISSN | 2090-3014 |
| IngestDate | Tue Sep 17 20:50:57 EDT 2024 Sat Aug 17 01:11:13 EDT 2024 Wed Oct 16 18:01:35 EDT 2024 Tue Oct 15 04:50:17 EDT 2024 Tue Oct 15 02:43:24 EDT 2024 Fri Nov 22 00:08:18 EST 2024 Sat Sep 28 07:54:25 EDT 2024 Sun Jun 02 18:55:49 EDT 2024 Wed Nov 06 05:55:15 EST 2024 Tue Oct 01 22:51:20 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2013 |
| Language | English |
| License | This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a535t-ea41a175b32f07d058f74e1c2e8c4f7ff0f651b29adb0c249ed368d0b64d05ce3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Academic Editor: Philippe Maincent |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818897/ |
| PMID | 24232077 |
| PQID | 1459153696 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3818897 proquest_miscellaneous_1459153696 gale_infotracmisc_A376681197 gale_infotracacademiconefile_A376681197 gale_healthsolutions_A376681197 crossref_primary_10_1155_2013_870579 pubmed_primary_24232077 hindawi_primary_10_1155_2013_870579 emarefa_primary_504926 airiti_journals_P20151203006_201312_201709060024_201709060024_283_291 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-01 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Cairo, Egypt |
| PublicationPlace_xml | – name: Cairo, Egypt – name: Egypt |
| PublicationTitle | Journal of Drug Delivery |
| PublicationTitleAlternate | J Drug Deliv |
| PublicationYear | 2013 |
| Publisher | Hindawi Limiteds Hindawi Puplishing Corporation Hindawi Publishing Corporation John Wiley & Sons, Inc |
| Publisher_xml | – name: Hindawi Limiteds – name: Hindawi Puplishing Corporation – name: Hindawi Publishing Corporation – name: John Wiley & Sons, Inc |
| References | (3) 2007; 341 (4) 2005; 8 (5) 1998; 87 (2) 2001; 229 (7) 2002; 4 (1) 1988; 25 (9) 2012; 434 (10) 2012; 45 (6) 2002; 62 (8) 2006; 34 9649356 - J Pharm Sci. 1998 Jul;87(7):867-72 16501004 - Drug Metab Dispos. 2006 May;34(5):862-9 15946594 - J Pharm Pharm Sci. 2005 Jan 12;8(1):18-25 11604272 - Int J Pharm. 2001 Oct 23;229(1-2):193-203 12368570 - J Clin Hypertens (Greenwich). 2002 Sep-Oct;4(5):325-31 17498898 - Int J Pharm. 2007 Aug 16;341(1-2):26-34 22677418 - Int J Pharm. 2012 Sep 15;434(1-2):122-32 3358900 - Br J Clin Pharmacol. 1988 Mar;25(3):387-96 12076183 - Drugs. 2002;62(9):1345-53; discussion 1354-6 2 3 5 8 |
| References_xml | – volume: 34 start-page: 862 issue: 5 year: 2006 end-page: 869 ident: 8 article-title: OATP1B1, OATP1B3, and Mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker publication-title: – volume: 25 start-page: 387 issue: 3 year: 1988 end-page: 396 ident: 1 article-title: Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985) publication-title: – volume: 45 start-page: 15 issue: 4 year: 2012 end-page: 27 ident: 10 article-title: Investigation of avalanche time and carr’s index of poultry litter powder as flowability indices publication-title: – volume: 62 start-page: 1345 issue: 9 year: 2002 end-page: 1353 ident: 6 article-title: Olmesartan medoxomil publication-title: – volume: 341 start-page: 26 issue: 1-2 year: 2007 end-page: 34 ident: 3 article-title: Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine) publication-title: – volume: 229 start-page: 193 issue: 1-2 year: 2001 end-page: 203 ident: 2 article-title: Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability publication-title: – volume: 434 start-page: 112 issue: 1-2 year: 2012 end-page: 132 ident: 9 article-title: Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles publication-title: – volume: 8 start-page: 18 issue: 1 year: 2005 end-page: 25 ident: 4 article-title: The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts publication-title: – volume: 4 start-page: 325 issue: 5 year: 2002 end-page: 331 ident: 7 article-title: Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements publication-title: – volume: 87 start-page: 867 issue: 7 year: 1998 end-page: 872 ident: 5 article-title: evaluation of hydrocortisone liquisolid tablets publication-title: – volume: 8 start-page: 18 issue: 1 year: 2005 ident: 4 publication-title: Journal of Pharmacy and Pharmaceutical Sciences – ident: 2 doi: 10.1016/S0378-5173(01)00867-5 – volume: 4 start-page: 325 issue: 5 year: 2002 ident: 7 publication-title: Journal of Clinical Hypertension doi: 10.1111/j.1524-6175.2002.01051.x – ident: 5 doi: 10.1021/js970346g – ident: 8 doi: 10.1124/dmd.105.008888 – volume: 434 start-page: 112 issue: 1-2 year: 2012 ident: 9 publication-title: International Journal of Pharmaceutics – volume: 62 start-page: 1345 issue: 9 year: 2002 ident: 6 publication-title: Drugs doi: 10.2165/00003495-200262090-00005 – volume: 45 start-page: 15 issue: 4 year: 2012 ident: 10 publication-title: Cercetări Agronomice În Moldova doi: 10.2478/v10298-012-0061-2 – volume: 25 start-page: 387 issue: 3 year: 1988 ident: 1 publication-title: British Journal of Clinical Pharmacology doi: 10.1111/j.1365-2125.1988.tb03318.x – ident: 3 doi: 10.1016/j.ijpharm.2007.03.034 |
| SSID | ssj0000480970 |
| Score | 2.0154166 |
| Snippet | Olmesartan medoxomil is an angiotensin type II receptor blocker, antihypertensive agent, administered orally. It is highly lipophilic (log P 5.5) and a poorly... Olmesartan medoxomil is an angiotensin type II receptor blocker, antihypertensive agent, administered orally. It is highly lipophilic (log P 5.5) and a poorly... |
| SourceID | pubmedcentral proquest gale crossref pubmed hindawi emarefa airiti |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 283 |
| SubjectTerms | Bioavailability |
| Title | Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil |
| URI | https://www.airitilibrary.com/Article/Detail/P20151203006-201312-201709060024-201709060024-283-291 https://search.emarefa.net/detail/BIM-504926 https://dx.doi.org/10.1155/2013/870579 https://www.ncbi.nlm.nih.gov/pubmed/24232077 https://search.proquest.com/docview/1459153696 https://pubmed.ncbi.nlm.nih.gov/PMC3818897 |
| Volume | 2013 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYikpcEK9CSgEjULk0XceJHedYlV1ViMJKFIlbZDuOGqmbFLKr0n_PjJNNmwpx4LRZZeI8ZsbzTTLzmZD31vHSCCXDzElIUDKtQ1NkLGSmiAy-0i_9cm8n39IvP9THGdLkiE0vjC_at6Y6rC-Wh3V17msrL5d2uqkTmy5OjzHKqCydTsgEsOGtFN1Pv4limV8kjjM4KaYMfV8ehE7I9aN4CjYqUuQLRTDBWQqh6b6ukERoFJ223VLDhh5m6-1zzJOvqr-h0btFlbei1PwRedjDS3rU3cZjcs_VT8j-ouOnvj6gZzftVu0B3aeLG-bq66fk0xwQbL-eF9V1QWcDFzhtSvq5-rmuwFargvppxK5aCpiXfsWuBnhyuqanrmh-N8vq4hn5Pp-dHZ-E_WILoRaxWIVOJ5EGLGFiXrK0YEKVaeIiy52ySZmWJSuliAzPdGGYhaTNFbFUBTMyAWHr4h2yVTe1e0EoQBLseE0Fz5D7RyojjTEScDxkc65kAZl1Tzvv_aXNF6AXgB5gHEzmqKOI408KGsQPh8mdPyrOeRYFYGq9svLLjpsj9zmNEH6MvNNzQHZ6RQ5SgiFPYkDeoF7zruN0cPX8CCZdqfD7akA-eAl0dlCq1X3PAtwn0maNJPdGkuCkdrT7XW87_77Stxu7ynEArH-rXbNuIUETGcQmmcFFP-_sbBhoY8QBSUcWOAggg_h4DziWZxLvHWn3v498SR5wvz4IvpPaI1urX2v3ikzaYv3ae-UfyPcyFA |
| link.rule.ids | 230,315,729,782,786,887,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfYYIIXvscCgxmBxsuyOh92ksdptCrQjkoUaW-WnThapDXZSCvYf8-dk2bLhHjYU1v56ji6n-8jufuZkI-p8XPNY-EmRkCCkijl6ixhLtOZp_GRfm6Pexv_iE5O489DpMnh614YW7Sf6uKwPF8clsWZra28WKSDdZ3YYDY9Ri8TJ9Fgg9yH_crYjSTdGuAwZok9Js5ncFlMGtrOPHCekO17wQBQyiNkDMVwwmcROKcHqkAaoZ5_2jILBV9UZ6-3zjBT_l38Kx69XVZ5w0-NntzxDp-Sx21gSo-a4Wfknimfk_1Zw2x9dUDn141a9QHdp7NrzuurF-TrCGLf9iQwqsqMDjsWcVrldFJcrgpAeZFRa4DSZU0hWqbfsR8CVqRKOjVZ9adaFOcvyc_RcH48dttjGlzFA750jQo9BVGIDvycRRnjcR6Fxkt9E6dhHuU5ywX3tJ-oTLMU0j2TBSLOmBYhCKcm2CabZVWaHUIhmMFe2Yj7CbIGiVgLrbWADADyQJMzhwwbLcl2p9VyBvqEoAVgxYRE3Xo-fkSgeXzlGN76EQfSTzwHQNoqWV40rB7SZkOc2zlkgw-HbLcA6KQ4Q4ZFh-whHmTTq9oZCXkE5lrE-GbWIZ-sBJoJAEOq2m4HuE8k3OpJ7vYkYXunveEPLeb-v9L3azxKnAAr50pTrWpI7XgCXk0ksOhXDT67idbgd0jUQ24ngNzj_REArOUgbwH6-s7_3CMPx_PpRE6-nHx7Qx759pQRfLK1SzaXv1bmLdmos9U7u7P_AngPR6g |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYYIgXvgeBwYxA42VZHSfOx-O0tRqwjUoMiTfLjm0t0poW2gr233PnpNkyIR7gqalycRz55_tI7n5HyLvScqdFnoaFTSFAKZQKtSlYyLSJNL7Sd77d29GX7PRbfjhEmpyu1ZdP2i91tVdfTPbq6tznVs4m5WCVJzYYnxyglcmLbDAzbrBGbsOeZfxaoO6VcJKzwreK4wxujYFDW50HBhQi_igeAFJFhqyh6FJwloGBuqMqpBLq2agNO1FwoDqdvXGO0fLP6k8-6c3Uymu2avTgP57yIbnfOqh0vxF5RG7Z-jHZGTcM15e79OyqYGu-S3fo-Ir7-vIJ-TgCH7jtCEZVbeiwYxOnU0ePq-_LCtBeGeoVUbmYU_Ca6Wesi4BZqZqeWDP9NZ1UF0_J19Hw7OAobNs1hErEYhFalUQKvBEdc8cyw0TussRGJbd5mbjMOeZSEWleKKNZCWGfNXGaG6bTBIRLG2-S9Xpa2-eEglODNbOZ4AWyB6W5TrXWKUQCEA9axwIybFZKtjtuLsewpuC8ALxYKnF9I44_Gaw-fnpMbvzJY8mLKACwtgstZw27h_RRkRB-DNlgJCCbLQg6KcGQaTEg24gJ2dSsdspC7oPaTnP8QhuQ914C1QUAolRt1QM8JxJv9SS3epKwzcve6bct7v4-0zcrTEocADPoajtdziHEEwVYt7SAST9rMNoNtNoAAcl66O0EkIO8fwZA67nIW5C--Ocrt8nd8eFIHn84_fSS3OO-2Qi-4Noi64sfS_uKrM3N8rXf3L8B-w9KKA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Formulation+and+evaluation+of+liquisolid+compacts+for+olmesartan+medoxomil&rft.jtitle=Journal+of+drug+delivery&rft.au=Prajapati%2C+Shailesh+T&rft.au=Bulchandani%2C+Hitesh+H&rft.au=Patel%2C+Dashrath+M&rft.au=Dumaniya%2C+Suresh+K&rft.date=2013-01-01&rft.issn=2090-3014&rft.volume=2013&rft.spage=870579&rft.epage=870579&rft_id=info:doi/10.1155%2F2013%2F870579&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2090-3014&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2090-3014&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2090-3014&client=summon |